Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 374

A Pilot Study of Infrared Thermal Imaging to Detect Active Bone Lesions in Children with Chronic Nonbacterial Osteomyelitis

9:00AM-11:00AM: Abstract Number: 373

a Retrospective Study of Clinical Factors Influencing the Development of Overlapping Disease Features in Pediatric Patients with Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Spondyloarthropathies (SpA)

9:00AM-11:00AM: Abstract Number: 386

Analysis of the Effectiveness of Immunization with Pneumococcal Polysaccharide Vaccine in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 364

Canakinumab First or Second Choice in Systemic Juvenile Idiopathic Arthritis – Experience from Clinical Practice

9:00AM-11:00AM: Abstract Number: 365

Canakinumab Treatment in Patients with Still’s Disease: A Pooled Analysis of Systemic Juvenile Idiopathic Arthritis Data By Age Groups

9:00AM-11:00AM: Abstract Number: 375

Controlled Discontinuation of Colchicine Therapy in Familial Mediterranean Fever Patients with Single MEFV Mutation

9:00AM-11:00AM: Abstract Number: 381

Down’s Arthritis (DA) – Clinical and Radiological Features of Arthritis in Children with Trisomy 21

9:00AM-11:00AM: Abstract Number: 368

Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 379

H Syndrome: Five New Cases from the United States with Novel Features and Responses to Therapy

9:00AM-11:00AM: Abstract Number: 369

Hepatitis A Virus Vaccination in Juvenile-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 383

Immunogenicity of 13 Valent Pneumococcal Vaccine in Children with Lupus: Single Center Experience in South Texas

9:00AM-11:00AM: Abstract Number: 376

Improvement of Disease Activity in Patients with Colchicine-Resistant FMF, Hids/Mkd and TRAPS Assessed By Autoinflammatory Disease Activity Index (AIDAI): Results from a Randomized Phase III Trial

9:00AM-11:00AM: Abstract Number: 367

Interleukin-1 Receptor Antagonist Is a Potential Treatment for Undifferentiated Autoinflammatory Syndromes

9:00AM-11:00AM: Abstract Number: 371

Longer Term Outcomes of Chronic Relapsing Multifocal Osteomyelitis in a UK Tertiary Adolescent and Young Adult Rheumatology Centre

9:00AM-11:00AM: Abstract Number: 378

Musculoskeletal Features in Copa Syndrome

9:00AM-11:00AM: Abstract Number: 377

Novel Insights into Periodic Fever Syndromes

9:00AM-11:00AM: Abstract Number: 372

Phenotype of Chronic Recurrent Multifocal Osteomyelitis in a Tertiary Referral Centre: The Great Ormond Street Hospital Experience

9:00AM-11:00AM: Abstract Number: 384

Protection Against Hepatitis B in Immunocompromised Pediatric Rheumatology and Gastroenterology Patients

9:00AM-11:00AM: Abstract Number: 382

Radiological Features Identified in the Hands of Children with Down Syndrome and Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 385

Reliable Implementation of a Hepatitis B Serology Screening and Vaccination Process for Immunocompromised Pediatric Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 366

Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom

9:00AM-11:00AM: Abstract Number: 380

Treatment Outcomes of Down Syndrome Arthropathy

9:00AM-11:00AM: Abstract Number: 370

Validation of 2016 ACR/EULAR Classification Criteria of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis in Japanese Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].